Immatics (NASDAQ:IMTX) Shares Down 4.9% - Should You Sell?

Immatics (NASDAQ:IMTX - Get Free Report) traded down 4.9% during mid-day trading on Monday . The stock traded as low as $5.69 and last traded at $5.68. 186,320 shares were traded during trading, a decline of 78% from the average session volume of 830,826 shares. The stock had previously closed at $5.97.

Analyst Ratings Changes

A number of equities analysts recently issued reports on IMTX shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Immatics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price target for the company. Wall Street Zen lowered Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Immatics in a report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $14.67.

Immatics Stock Performance

The company has a market cap of $746.32 million, a P/E ratio of -9.30 and a beta of 0.83. The stock has a 50-day moving average of $4.86 and a two-hundred day moving average of $5.47.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $20.12 million during the quarter, compared to analyst estimates of $14.92 million. Research analysts predict that Immatics will post -0.72 EPS for the current year.

Institutional Trading of Immatics

A number of institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. increased its holdings in shares of Immatics by 38.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock worth $66,194,000 after purchasing an additional 4,072,226 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Immatics by 7.6% in the 4th quarter. Wellington Management Group LLP now owns 10,417,892 shares of the company's stock worth $74,071,000 after purchasing an additional 736,709 shares in the last quarter. Baker BROS. Advisors LP increased its holdings in shares of Immatics by 12.9% in the 4th quarter. Baker BROS. Advisors LP now owns 7,275,830 shares of the company's stock worth $51,731,000 after purchasing an additional 832,432 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Immatics by 14.6% in the 1st quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock worth $32,439,000 after purchasing an additional 917,700 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its holdings in shares of Immatics by 38.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock worth $38,496,000 after purchasing an additional 1,509,547 shares in the last quarter. Institutional investors own 64.41% of the company's stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.